Results 61 to 70 of about 487,201 (201)
Unbalanced rearrangement der(9;18)(p10;q10) in a patient with polycythemia vera [PDF]
Case report of a translocation : Unbalanced rearrangement der(9;18)(p10;q10) in a patient with polycythemia ...
Raca, G +15 more
core +1 more source
Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer +2 more
doaj +1 more source
Burning feet in polycythemia vera – peripheral sensorimotor axonal neuropathy with erythromelalgia
Uwe Wollina Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany Abstract: Polycythemia vera is a rare myeloproliferative disease. Cutaneous symptoms are uncommon.
Wollina U
core
Evaluating the impact of cardiovascular (CV) risk factors on overall survival (OS) in polycythemia vera (PV)
Gverić-Krečak, Velka +6 more
core +1 more source
Myelopathy due to Spinal Extramedullary Hematopoiesis in a Patient with Polycythemia Vera
Extramedullary hematopoiesis (EMH) occasionally occurs in patients exhibiting hematological disorders with decreased hematopoietic efficacy. EMH is rarely observed in the spinal epidural space and patients are usually asymptomatic.
Shuhei Ito +10 more
doaj +1 more source
We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and pentraxin 3 might be correlated with cardiovascular complications in patients with essential thrombocythemia and polycythemia vera.
Tiziano Barbui +15 more
doaj +1 more source
Prevention of thrombosis in polycythemia vera and essential thrombocythemia
Identifying the most safe and effective strategy for reducing the vascular risk of subjects with polycythemia vera and essential thrombocythemia has always been challenging.
Landolfi, Raffaele, Di Gennaro, Leonardo
core +1 more source
Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis
Here we critically evaluate the role of elevated hematocrit as the principal determinant of thrombotic risk in polycythemia and erythrocytosis, defined by an expansion of red cell mass.
Victor R. Gordeuk +2 more
doaj +1 more source
Interferon-␣ (IFN-␣) is a nonleukemogenic treatment of polycythemia vera ...
Bruno Cassinat +9 more
core
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Up to 20% of patients with polycythemia vera have karyotypic abnormalities at the time of the initial diagnosis. However, the cytogenetic abnormalities in polycythemia vera have not been well characterized and their prognostic impact is largely unknown ...
Guilin Tang +13 more
doaj +1 more source

